<DOC>
	<DOCNO>NCT01007201</DOCNO>
	<brief_summary>This laboratory-blinded study healthy toddler , child , teenager design investigate safety , reactogenicity , immunogenicity inactivate influenza H1N1 vaccine ( AdimFlu-S ) . There 3 age stratum , contain least 50 subject : great equal 1 year less 3 year , great equal 3 year less 6 year , great equal 6 year less 18 year . In age stratum , eligible subject receive 2 injection AdimFlu-S ( A/H1N1 ) designate dosage level ( 7.5 μg , 15 μg 15 μg 1~ &lt; 3 , 3~ &lt; 6 6~ &lt; 18 year , respectively ) 3 week apart . Following immunization , safety measure assessment adverse event 6 week follow first vaccination , serious adverse event new-onset chronic medical condition 7 month post first vaccination , reactogenicity vaccine 7 day follow vaccination . Immunogenicity test include hemagglutination inhibition ( HAI ) test serum obtain first vaccination , three six week first vaccination .</brief_summary>
	<brief_title>Immunogenicity Safety Influenza Virus Vaccine , AdimFlu-S ( A/H1N1 ) , Pediatric Population</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Boys girl age ≧ 1 year old 18 year old day first vaccination ; Subject and/or parent ( ) /legal guardian ( ) willing comply plan study procedure available study visit ; Subject good physical health basis medical history , physical examination ; Subject and/or parent ( ) /legal guardian ( ) must read sign studyspecific inform consent prior initiation study procedure . Subject ever receive influenza vaccine within previous 6 month ; History hypersensitivity egg egg protein similar pharmacological effect study medication ( AdimFluS ( A/H1N1 ) ) ; Personal family history GuillainBarré Syndrome ; An acute febrile illness within last 72 hour prior vaccination ; Subject bleed disorder coagulation disorder need receipt anticoagulant 3 week precede inclusion contraindicate intramuscular injection ; Subjects influenzalike illness define presence fever ( temperature ≧38.5℃ ) least two follow four symptom : headache , muscle/joint ache pain ( e.g . myalgia/arthralgia ) , sore throat cough ; Female subject pregnant , lactate likely become pregnant study ; Women childbearing potential disagree use acceptable method contraception ( e.g. , hormonal contraceptive , IUD , barrier device abstinence ) throughout study ; Treatment investigational drug device , participation clinical study , within 3 month consent ; Immunodeficiency , immunosuppressive household contact immunosuppression ; History wheeze bronchodilator use within 3 month prior study vaccine ; Receipt live virus vaccine within 1 month prior study vaccination expect receipt within 2 month first study vaccination ; Receipt inactivate vaccine within 2 week prior study vaccination expect receipt vaccination within 3 week immunogenicity evaluation period ; Receipt blood product , include immunoglobulin prior 3 month ; Underlying condition investigator 's opinion may inappropriate vaccination ; Significant chronic illness inactivate influenza vaccine recommend commonly use .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>H1N1</keyword>
	<keyword>vaccine</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>